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Abstract
More than 50 genomic regions have now been shown to influence the risk of multiple sclerosis (MS). However, the
mechanisms of action, and the cell types in which these associated variants act at the molecular level remain largely
unknown. This is especially true for associated regions containing no known genes. Given the evidence for a role for B cells
in MS, we hypothesized that MS associated genomic regions co-localized with regions which are functionally active in B
cells. We used publicly available data on 1) MS associated regions and single nucleotide polymorphisms (SNPs) and 2)
chromatin profiling in B cells as well as three additional cell types thought to be unrelated to MS (hepatocytes, fibroblasts
and keratinocytes). Genomic intervals and SNPs were tested for overlap using the Genomic Hyperbrowser. We found that
MS associated regions are significantly enriched in strong enhancer, active promoter and strong transcribed regions
(p=0.00005) and that this overlap is significantly higher in B cells than control cells. In addition, MS associated SNPs also
land in active promoter (p=0.00005) and enhancer regions more than expected by chance (strong enhancer p=0.0006;
weak enhancer p=0.00005). These results confirm the important role of the immune system and specifically B cells in MS
and suggest that MS risk variants exert a gene regulatory role. Previous studies assessing MS risk variants in T cells may be
missing important effects in B cells. Similar analyses in other immunological cell types relevant to MS and functional studies
are necessary to fully elucidate how genes contribute to MS pathogenesis.
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Introduction
Multiple sclerosis (MS) is a complex immune mediated disorder of
thecentralnervoussystem whicharises from acombinationofgenetic
and environmental factors and their interactions [1]. A recent
genome wide association study (GWAS) involving more than nine
thousand MS patients found evidence for association of MS with 57
genomic regions [2]. However, there remains limited understanding
as to how these variants are involved in MS development.
Although T cells have traditionally been thought to mediate MS
pathophysiology, attention to the role of B cells is increasing [3–4].
The success of Rituximab (an anti-CD20 monoclonal antibody)
[5] heightened this interest, and a number of other anti-CD20
monoclonal antibodies are undergoing clinical trials [6].
The regulation of genes can be just as important as the
proteins they encode. Regulatory elements in the genome are
much harder to identify than protein-coding genes because they
lack distinguishing sequence signatures. Moreover, many regu-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32281latory elements function only in certain cell types and conditions
[7].
Chromatin profiling is a powerful means of genome annotation
and detection of regulatory activity. The chromatin landscape of a
cell is distinctive for a specific cell type and among other roles
determines which regions of the genome are accessible to the
binding of transcription factors and whether transcription occurs
or is repressed. A recent study mapped a number of chromatin
marks across nine cell types to systematically characterize
regulatory elements and their cell-type specificities. These included
enhancer elements (DNA sequences able to modulate gene
expression through the binding of transcription factors to them),
promoter regions (DNA regions located near the transcription start
site of a gene which facilitate the binding of RNA polymerase and
the initiation of transcription), polycomb repressed (DNA regions
in which gene expression is actively repressed by the binding of
polycomb group proteins), heterochromatin (large portions of
DNA which are densely packed and therefore less accessible to
transcription factors), insulator sites (DNA elements bound by the
zinc finger protein CTCF which functions as an enhancer-
blocking element), transcribed regions and finally repetitive/copy
number variations (CNV, DNA regions characterized by a
variable number of copies between individuals). Among the cell
types profiled were B cells, hepatocytes, fibroblasts and keratino-
cytes [8].
A large proportion of SNPs associated with MS do not lie in the
coding regions of genes and therefore are likely to influence disease
risk through a gene regulatory role. It is plausible that genetic
variants associated with a certain disease act through influencing
the particular cell type(s) that trigger disease onset. Therefore, one
would expect to observe an overlap between genomic regions
associated with disease risk and those which are active in the
causative cell type(s). The aim of this study was to assess whether
genomic regions that have been associated with MS significantly
overlap with active regulatory regions in B cells and whether this
overlap is higher than that observed in non-immunological cell
types. This potentially provides us with relevant information
regarding the importance of the immune system and B cells as
mediators of disease in MS.
Methods
Data acquisition
Genetic variants associated with MS risk were obtained from
the recent GWAS performed by the International Multiple
Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust
Case Control Consortium 2 (WTCCC2) [2]. MS regions were
defined as genomic intervals of 0.25 cM centred on the lead
associated SNP. The chromatin profiles of B-lymphoblastoid cells
(GM12878), hepatocellular carcinoma cells (HepG2), normal lung
fibroblasts (NHLF) and normal epidermal keratinocytes (NHEK)
were obtained from the ENCODE project [8]. Briefly, chromatin
immunoprecipitation followed by massively parallel DNA se-
quencing (ChIP-seq) and expression data were used to identify
different classes of chromatin states: active promoter (AP), weak
promoter (WP), poised promoter (PP), strong enhancer (SE), weak
enhancer (WE), polycomb repressed (PR), heterochromatic (H),
insulator (I), strongly transcribed (ST), weakly transcribed (WT)
and repetitive/CNV (Rep/CNV) [8].
Overlap analysis
All analyses were performed using the Genomic Hyperbrowser
(http://hyperbrowser.uio.no/hb/) [9]. The enrichment of MS
regions in a certain chromatin state (e.g. AP) was calculated as the
ratio of the proportion of AP intervals covered by MS regions, to
the proportion of non-AP intervals covered by MS regions. In
order to assess whether the overlap between MS regions and a
certain chromatin state was higher than expected by chance, a
permutation based analysis was performed. We defined a null
model for which the location of individual chromatin intervals
varied randomly, while preserving the empirical segment and
inter-segment length distribution of chromatin intervals. MS
regions were fixed. The number of overlapping base pairs between
the two tracks was calculated for the real data, as well as for 20,000
Monte Carlo samples from the null model. The p-value was
calculated in the usual way, i.e. as the proportion of Monte Carlo
samples being equal to or more extreme than the observed
overlap. These analyses were performed on both a global (whole
genome) and local (chromosome arms) scale and for each cell type.
For local analyses p-values were adjusted to a FDR of 10%.
When comparing B cells to non immunological cell types, case-
control tracks were created for each chromatin state by removing
all parts of chromatin intervals that overlapped between B and
control cells and marking the remaining intervals as case (B cell
specific intervals) and control (other cell type specific intervals). P-
values were computed by a Monte Carlo procedure, in which the
case-control labels of chromatin intervals were randomly permut-
ed. The observed base pair overlap between case intervals and MS
regions were compared against the corresponding distribution for
20,000 Monte Carlo samples in the usual way. The fold
enrichment difference in overlap between B and control cells
was calculated as the ratio between the proportions of case and
control intervals that overlapped with MS regions.
Finally we tested whether MS associated SNPs (primary SNPs)
and SNPs in perfect linkage disequilibrium (LD) with primary
SNPs (r
2=1) were located within certain chromatin states more
than expected by chance as described above for MS regions.
Results
Active chromatin states in B cells overlap with MS
regions
Our first aim was to assess whether and where in the genome a
particular chromatin state in B cells significantly overlapped with
MS regions. The enrichment of MS regions in different chromatin
states and the significance of the overlap are presented in Table 1.
On a global scale (whole genome) enrichment values varied
considerably between different chromatin states ranging from 0.34
in H to 3.07 in SE regions. When testing statistical significance,
MS regions overlapped with promoter (AP and WP p=0.00005;
PP p=0.0005), enhancer (p=0.00005) and transcribed (p=
0.00005) regions more than expected by chance.
In order to assess whether the significant global overlap was
homogeneously distributed across the genome or resulted from
particularly highly enriched regions, the same analysis was
performed on a local scale by dividing the whole genome into
chromosome arms. This resulted in 43 different ‘bins’ of which 17
had to be excluded due to the absence of MS associated regions in
those chromosome arms leaving a total of 26 bins. Out of these
26 bins, statistically significant overlap was found in 18 for AP, 15
for WP, 7 for PP, 23 for SE, 24 for WE, 3 for PR, 0 for H, 2 for I,
9 for ST, 9 for WT and 1 for Rep/CNV chromatin states
(Table 1). As expected, the chromatin states with significant
overlap on a global scale were those with the highest number of
significant bins. SE and WE regions showed the most homoge-
neously distributed overlap, being significant in all but 3 and
2 bins respectively. The overlap of promoter and transcribed
regions appeared more dependent on particular bins.
The Role of MS Genomic Regions in B Cells
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32281Active chromatin states in B cells overlap with MS
regions more than in non immunological cell types
On its own, the presence of an overlap between MS regions and
active chromatin states in B cells is not sufficient to indicate that B
cells are relevant to MS pathogenesis. Both MS regions and active
chromatin states could just be more likely to be near commonly
transcribed genes, giving rise to co-localization in the absence of
any direct relationship between the MS-associated regions and
chromatin states. To rule out this hypothesis we tested 3 additional
cell types (hepatocytes, fibroblasts and keratinocytes) that, based
on current knowledge, are not implicated in MS pathogenesis.
Enrichment values, global significance and number of significant
bins are presented in Table 2.
Similarly to findings observed in B cells, promoter, enhancer
and transcribed regions overlapped with MS regions more than
expected by chance in all control cell types. However, the number
of significant bins as well as the enrichment values tended to be
higher in B cells than in other cell types. We explored this further
by directly comparing the overlap in B cells with that of the control
cells (Table 3). Strikingly the overlap between MS regions and AP,
SE, WE and ST regions was significantly higher in B cells than in
any of the other cell types. The highest fold enrichment differences
were observed for higher activity states (AP, SE and ST).
MS associated SNPs preferentially land in active
promoter and enhancer regions
The presence of significant overlap between MS regions and
certain active chromatin states in B cells supports an important
role for the immune system in MS but does not provide any insight
into how MS risk variants may be acting. We attempted to answer
this question by looking at where in the genome MS associated
SNPs, and SNPs in perfect LD (r
2=1), preferentially land. A total
of 452 SNPs were tested and enrichment of chromatin states for
MS SNPs and significance of overlap are presented in Table 4. MS
Table 2. Enrichment, global significance and number of significant bins in B and control cells.
CHROMATIN STATE MEASURE B CELLS HEPATOCYTES FIBROBLASTS KERATINOCYTES
Global significance YES (p=0.00005) YES (p=0.00005) YES (p=0.00005) YES (p=0.00015)
Active promoter Significant bins 18 9 11 6
Global enrichment 2.721 2.114 2.207 1.95
Global significance YES (p=0.00005) YES (p=0.00005) YES (p=0.0001) YES (p=0.00005)
Weak promoter Significant bins 15 11 7 10
Global enrichment 2.134 2.121 1.803 1.949
Global significance YES (p=0.0005) Maybe (p=0.01975) YES (p=0.0022) YES (p=0.0013)
Poised promoter Significant bins 7 5 44
Global enrichment 2.352 1.935 2.057 2.011
Global significance YES (p=0.00005) YES (p=0.0016) YES (p=0.00005) YES (p=0.00065)
Strong enhancer Significant bins 23 1 6 7
Global enrichment 3.074 1.908 1.886 1.577
Global significance YES (p=0.00005) YES (p=0.00005) YES (p=0.00035) YES (p=0.00005)
Weak enhancer Significant bins 24 12 4 10
Global enrichment 2.222 1.747 1.436 1.528
Global significance Maybe (p=0.07035) NO (p=0.6002) YES (p=0.0056) NO (p=0.1098)
Polycomb repressed Significant bins 3 1 8 5
Global enrichment 1.355 1.161 1.574 1.314
Global significance NO (p=1) NO(p=1) NO(p=1) NO(p=1)
Heterochromatic Significant bins 0 0 0 0
Global enrichment 0.3363 0.4589 0.4273 0.4829
Global significance Maybe (p=0.08100) Maybe (p=0.02090) YES (p=0.0015) YES (p=0.00025)
Insulator Significant bins 2 5 47
Global enrichment 1.205 1.267 1.348 1.376
Global significance YES (p=0.00005) YES (p=0.0004) YES (p=0.0007) YES (p=0.005)
Strong transcribed Significant bins 97 8 7
Global enrichment 2.575 2.171 2.133 1.868
Global significance YES (p=0.00005) YES (p=0.0008) YES (p=0.00005) YES (p=0.00005)
Weak transcribed Significant bins 93 8 7
Global enrichment 1.919 1.668 1.836 1.811
Global significance NO (p=0.3547) Maybe (p=0.02565) NO (p=0.5321) NO (p=0.1582)
Repetitive/CNV Significant bins 1 1 1 1
Global enrichment 1.013 1.965 0.8118 1.351
doi:10.1371/journal.pone.0032281.t002
The Role of MS Genomic Regions in B Cells
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32281SNPs were located within AP, SE and WE intervals more than
expected by chance. Weak evidence for overlap was also observed
for WP, ST and WT regions.
When examined in the light of the chromatin data, several regions
seemed particularly interesting. For example MS associated SNPs in
the regions of CLECL1, CD86,TYK2 and CD58 land in promoter and
enhancer regions which are present in B cells but not in other cell
types (Figure 1). Wealso looked at the position of MS SNPs in regions
in which no candidate genes have been identified. Interestingly,
rs12466022 on chromosome 2 and respective SNPs in LD landed in
WE and SE intervals, while rs13192841 on chromosome 6 and
respective SNPs in LD were located in WE and WT regions. The
complete list of SNPs and overlapping chromatin states is available in
supplementary material online (Table S1).
Discussion
MS is a complex disorder of unknown aetiology. Here we show
that genomic regions associated with MS overlap with AP, SE,
WE and ST regions in B cells and that this occurs more than
would be expected by chance, and more than was observed in 3
other cell types unrelated to MS pathogenesis. Notably, the
overlap was particularly striking in SE and WE regions for which
significance was reached in 23 and 24 out of the 26 analyzed bins
respectively. This is in accordance with the previous observations
that tissue-specific genes appear more dependent on enhancer
than promoter elements [8]. Furthermore, we provide evidence
that the associated SNPs preferentially land in promoter, enhancer
and to a lesser extent transcribed regions. These findings have
several important implications.
Firstly, this work further supports the immunological aetiology
of MS [10]. Our findings are in agreement with those of a gene-
ontology analysis of the genes located within MS associated
regions, which showed a substantial overrepresentation of
immune-related processes [2]. As compared to this type of
analysis, our approach has the relative advantage of being
independent of what is currently known on genes and cell types.
Secondly our observations provide further support for an
important role for B cells in the pathogenesis of MS. The presence
of oligoclonal bands in the cerebrospinal fluid is the most
Table 3. Comparison of overlaps between B cells and other cell types.
Chromatin state Is overlap in B cells.Hepatocytes? Is overlap in B cells.Fibroblasts? Is overlap in B cells.Keratinocytes?
Significance Fold difference Significance
Fold
difference Significance
Fold
difference
Active promoter YES (p=0.0001) 1.958 YES (p=0.0006) 1.888 YES (p=0.00005) 2.747
Weak promoter NO (p=0.5972) 1.022 YES (p=0.00075) 1.239 YES (p=0.0025) 1.068
Poised promoter YES (p=0.00945) 1.259 Maybe (p=0.07815) 1.208 NO (p=0.2274) 1.255
Strong enhancer YES (p=0.00005) 1.709 YES (p=0.00005) 1.772 YES (p=0.00005) 2.196
Weak enhancer YES (p=0.00005) 1.306 YES (p=0.00005) 1.626 YES (p=0.00005) 1.513
Polycomb repressed NO (p=0.1456) 1.213 NO (p=1) 0.8860 NO (p=0.9866) 1.119
Heterochromatic NO (p=1) 0.5286 NO(p=1) 0.5938 NO (p=1) 0.4705
Insulator NO (p=0.7215) 0.8227 NO (p=0.3529) 0.9084 NO (p=0.9425) 0.8002
Strong transcribed YES (p=0.0015) 1.486 YES (p=0.00005) 1.417 YES (p=0.00005) 2.027
Weak transcribed Maybe (p=0.07585) 1.230 NO (p=0.1152) 1.096 NO (p=0.1358) 1.132
Repetitive/CNV NO (p=1) 0.1713 NO(p=0.2893) 2.492 NO (p=0.9999) 0.4362
doi:10.1371/journal.pone.0032281.t003
Table 4. Enrichment and significance of the overlap between MS SNPs and chromatin states in B cells.
Chromatin state MS SNPs Significance Enrichment
Number Percentage
Active promoter 30 6.64 YES (p=0.00005) 9.202
Weak promoter 9 1.99 Maybe (p=0.0413) 2.907
Poised promoter 2 0.44 NO (p=0.181) 2.72
Strong enhancer 35 7.74 YES (p=0.0006) 4.878
Weak enhancer 57 12.61 YES (p=0.00005) 4.580
Polycomb repressed 9 1.99 NO (p=0.7278) 0.63
Heterochromatic 162 35.84 NO (p=1) 0.216
Insulator 4 0.88 NO (p=0.2574) 1.634
Strong transcribed 59 13.05 Maybe (p=0.0529) 2.271
Weak transcribed 85 18.81 Maybe (p=0.0357) 1.973
Repetitive/CNV 0 0.00 NO (p=1) 0
doi:10.1371/journal.pone.0032281.t004
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abnormal B cell activation within the CNS of MS patients [11].
Furthermore B cell abnormalities influence both conversion to
clinically definite MS, MRI activity, onset of relapses and disease
progression [12–17]. Possibly the strongest evidence for B cells in
MS comes from clinical trials showing that MRI activity and onset
of relapses are significantly decreased after depletion of CD20+ B
cells [5]. However, we must consider that certain chromatin
features may be shared between B and other immune cell types, in
particular T cells. Unfortunately a similarly detailed chromatin
profile of T cells is not yet available and therefore a direct
comparison between B and T cells could not be performed. Even if
similar chromatin profiles exist between T and B cells, the
attempts to understand the effects of genetic risk variants on T cell
function [18] may be missing important effects in B cells. Given
the increasing evidence for B-T cell interactions in MS [19–21],
this analysis has the potential to greatly help the dissection of the
roles played by these two cell types.
When MS SNPs rather than MS regions were analyzed, we
found that MS SNPs were significantly more likely to land in AP,
SE and WE regions than expected by chance perhaps suggesting
that many of the associated SNPs may influence the risk of MS by
modifying the binding of transcription factors and transcription in
general. This is in agreement with previous observations [8]. For
MS associated SNPs landing in non-genic regions, for the first time
we are able to show a likely functional role in gene regulation.
However these findings should be interpreted with caution for two
reasons. First, the observed overlap between MS SNPs and active
chromatin states may be consequent to the fact that MS SNPs land
in MS regions, themselves enriched for active chromatin states.
Secondly, a conclusive answer to this question can only come from
functional studies which should investigate if and how MS variants
affect the chromatin landscape and gene expression.
To conclude, genomic regions associated to MS susceptibility
are active in B cells and causative SNPs may act by changing the
chromatin landscape. Further similar analyses in other immuno-
logical cell types relevant to MS and functional studies are
required to fully understand in which cells, at which stage and how
MS genetic variants are acting.
Supporting Information
Table S1 List of MS associated SNPs and SNPs in perfect LD
(r
2=1) with overlapping chromatin states.
(XLSX)
Figure 1. MS SNPs land in B cell specific promoter and enhancer elements in the regions of CLECL1, TYK2, CD86, and CD58 (a–d); MS
SNPs in a region with no candidate gene land in enhancer intervals (e). Chromatin states: AP=active promoter; WP=weak promoter;
PP=poised promoter; SE=strong enhancer; WE=weak enhancer; PR=polycomb repressed; H=heterochromatic; I=insulator; ST=strong
transcribed; WT=weak transcribed; CNV/Rep=CNV/repetitive. Cell lines: GM12878=B cells; HepG2=hepatocytes; NHEK=keratinocytes;
NHLF=fibroblasts.
doi:10.1371/journal.pone.0032281.g001
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